NATICK, MA – September 11, 2023 – Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that it has added two senior executives to the Company’s leadership team as it continues development of its diagnostic test portfolio and looks ahead to commercialization. Josh Gralapp has joined Mercy as Vice President for Marketing and Strategic Alliances, while Tim Membrino has joined as Vice President for Program and Portfolio Management.
“We continue to make rapid progress in the development of our screening tests for those at high risk of developing lung and ovarian cancer,” said Mercy CEO Dawn Mattoon. “Josh and Tim are exceptional leaders who share a passion for our mission to save lives and relieve suffering globally through the early detection of cancer. Their skills and experience will be instrumental as we execute our commercialization roadmap and look to expand and diversify our product pipeline.”
Josh most recently served as Vice President of Commercial for Delfi Diagnostics, where he developed the company’s product commercialization strategy for its early cancer detection/liquid biopsy technology. Previously, he held marketing leadership roles at Exact Sciences and Genomic Health with their urologic oncology diagnostic test portfolios. His depth and breadth of experience in diagnostic test commercialization has been an immediately impactful addition to Mercy’s leadership team. Josh holds an MBA from Santa Clara University and a BS in Chemistry from California State University, Chico.
“Cancer is a devastating illness that impacts all of us. With the company’s unique and cutting-edge extracellular shed vesicle (ESV) technology, laser-focused approach, and talented team, Mercy is uniquely positioned to deliver tests with unmatched performance and broad accessibility to those that need them the most,” Josh said. “I couldn’t be more excited to join this exceptional team and help bring transformative screening and diagnostic tests to patients everywhere.”
Tim comes to Mercy most recently from Quanterix Corporation, where he served as Vice President for Program and Portfolio Management, leading enterprise-wide initiatives across product development, operations, quality, information technology, and infrastructure. Prior to his tenure at Quanterix, he held Project Management Office (PMO) leadership roles in several leading life science companies, including Medtronic, Bio-Rad, and RainDance Technologies. Tim’s highly relevant experience in leading complex, cross-functional product development and business transformation initiatives as the PMO team leader has already enabled a significant increase in the velocity, visibility, and predictability of Mercy’s programs.
“The leadership and scientific talent at Mercy is experienced, focused and well positioned to drive the business and technology forward through development and commercialization,” said Tim. “I’m thrilled to join an executive team that embraces Program and Portfolio Management best practices paired with robust clinical development efforts as we drive Mercy’s test portfolio through the product realization life cycle.”
ABOUT MERCY BIOANALYTICS
Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo™ platform is designed to detect Stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate, and colorectal cancers combined.
Michelle McAdam, Chronic Communications Inc.